Latest News

Wednesday, May 23, 2018

New Type of Vertigo Defined That May Be Treatable

Neurologists have defined a new type of vertigo with no known cause (Neurology. 2018:published online May 23). The authors have differentiated this type of vertigo from serious causes of vertigo (eg, …

Read the full story

Wednesday, May 23, 2018

Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Pain

Topline results the first pivotal phase 3 clinical trial of intravenous (IV) tramadol (Avenue Therapeutics, New York, NY) have been released. Enrolled patients were randomized into 1 of 3 regimens: 50…

Read the full story

Tuesday, May 22, 2018

New Potential Model to Estimate Lifetime Risk of Alzheimer's Dementia Using Biomarkers For Preclinical Disease

According to an article published to in the journal Alzheimer’s and Dementia (Alzheim and Dement. 2018:published online May 22). Researchers from the Department of Biostatistics at University of…

Read the full story

Tuesday, May 22, 2018

FDA Clears Next-Generation Stent Retriever to Treat Ischemic Stroke

Cerenovus, part of the Johnson & Johnson Medical Devices Companies, announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Embotrap II revasculariza…

Read the full story

Monday, May 21, 2018

FDA Grants Breakthrough and Fast-Track Designations to Pitolisant for Treatment of Patients With Narcolepsy

The Food and Drug Administration (FDA) has granted fast-track and breakthrough therapy designations to the investigational therapy pitolisant (Harmony Biosciences, Plymouth Meeting, PA) for the treatm…

Read the full story

Friday, May 18, 2018

First Monoclonal Antibody Blocking CGRP Approved for Treatment of Migraine

The Food and Drug Administration today approved erenumab-aooe (Aimovig; Novartis, East Hanover, NJ) for prevention of migraine in adults. Erenumab is a monoclonal antibody that blocks the calcitonin g…

Read the full story

Thursday, May 17, 2018

Growing Evidence for Cannabidiol to Treat Lennox Gastaut Syndrome and Dravet Syndrome

Results of a phase 3 clinical trial comparing adjunctive treatment with cannabidiol (CBD) (Epidiolex; GW Pharmaceuticals/Greenwich Biosciences, Carlsbad, CA) to placebo showed that adding oral CBD to …

Read the full story

Wednesday, May 16, 2018

Potential New Rescue Therapy for Cluster Seizures, Midazolam Nasal Spray, Acquired by UCB

UCB has announced an agreement to acquire the rights to midazolam nasal spray (USL261), intended as a rescue therapy for acute repetitive series (ARS), or cluster seizures.  The company expects t…

Read the full story

Tuesday, May 15, 2018

Poor Blood-Pressure Control Related to More Lacunar Strokes at Earlier Age

While elevated blood pressure is a well-established risk factor for stroke, there has been debate regarding the roll of elevated blood pressure in lacunar stroke with some studies suggesting that hype…

Read the full story

Thursday, May 10, 2018

Retinal Deposits of Phosphorylated Alpha-Synuclein: A Biomarker for Parkinson’s Disease?

Analysis of retinas from 19 autopsied subjects, 9 with Parkinson’s disease (PD), and 4 with incidental Lewy body disease, showed accumulation of phosphorylated α‐synuclein (AS) that was …

Read the full story

Wednesday, May 09, 2018

FDA Issues Recommendation on Neurovascular Stents Used for Stent-Assisted Coiling of Unruptured Brain Aneurysm

The US Food and Drug Administration (FDA) has issued a letter to health care providers that gives recommendations on patient selection and use of neurovascular stents for stent-assisted coiling (SAC) …

Read the full story

Wednesday, May 09, 2018

Depression in Older Adults May Be Linked to Memory Loss

In a study published in the journal  Neurology, researchers Zeki Al Hazzour, Michelle R. Caunca, Juan Carlos Nobrega, and others showed that depression in older adults correlates to worse ba…

Read the full story

Tuesday, May 08, 2018

Amantadine-Extended Release: Different Pharmocokinetics Drive Different Clinical Effects

Amantadine-ER (Gocovri; Adamas, Emeryville, CA) is approved by the Food and Drug Administration (FDA) for treatment of dyskinesia in patients with Parkinson’s disease taking levodopa therapy wit…

Read the full story

Monday, May 07, 2018

Nonmotor Symptoms of Parkinson’s Disease Underreported and Undertreated

More than 2 in 3 patients with Parkinson’s disease (PD) or their caregivers affirm the presence of nonmotor symptoms that significantly and negatively affect their quality of life. Of 3,500 peop…

Read the full story

Friday, May 04, 2018

OnabotulinumtoxinA for Migraine Has Long-Term Safety and Efficacy

A wealth of results showing the long-term safety and efficacy of onabotulinumtoxinA (Botox; Allergan, Dublin, Ireland) for treating patients with migraine were presented at the recent American Academy…

Read the full story
Load More